A major EU project coordinated from UCD is set to push the frontiers of biomedical research by exploring the transformative potential of extracellular vesicles (EVs). EVs are small particles that act as messengers between cells which could transform early diagnosis and targeted treatments for diseases such as cancer and cardiovascular conditions. The project, which is coordinated by Professor Breandán Kennedy, is funded through the Marie Skłodowska-Curie Actions (MSCA) programme under Horizon Europe with a budget of €1,311,000 and will run for 48 months, starting in January 2025.
EVs are released by cells and carry proteins, lipids, and nucleic acids, making them key vehicles for cell-to-cell communication. EVEREST will focus on standardising methods for isolating and characterising these vesicles, facilitating their use in non-invasive diagnostics and personalised therapies to improve the precision and effectiveness of treatments for complex diseases. EVEREST represents a bold step forward in the quest for innovative medical solutions.
By harnessing the power of extracellular vesicles, we hope to pioneer new diagnostics and treatments that can transform lives. I am thrilled to lead this world-class consortium and look forward to the groundbreaking discoveries we will achieve together." Professor Breandán Kennedy Professor Kennedy is a Fellow of the UCD Conway Institute for Biomolecular and Biomedical Research, which will provide state-of-the-art research facilities an.